Biogen Hid Issues With Alzheimer's Drug, Investor Suit Claims

By Ivan Moreno · February 8, 2022, 6:05 PM EST

Biogen was hit with a proposed class action Monday from investors whose shares plummeted after a controversial new Alzheimer's drug failed to deliver the financial gains they expected....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Oklahoma Firefighters Pension and Retirement System v. Biogen Inc. et al

Case Number

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

February 07, 2022

Recent Articles By Ivan

October 22, 2024
IQVIA, Veeva Blast Summary Judgment Bids In Secrets Suit
October 08, 2024
Illumina Wants Unresponsive Plaintiff To Pay $200K, Atty Fees
September 25, 2024
Walgreens' TM Suit Can Proceed Against Founder's Relative
August 08, 2024
Pot Cos. Get Creative To Boost Brands Despite Feds' TM Ban
May 03, 2024
How Big IP Judgment Winners Are Insuring 'Nuclear Verdicts'
April 15, 2024
TTAB Sides With Pharma Co.'s Opposition To 'SageForth' TM
March 18, 2024
The Biggest Trade Secrets Awards In The Last 5 Years
January 05, 2024
Philips Blames SoClean For Breathing Machine Breakdowns
January 01, 2024
Copyright & Trademark Policy To Watch In 2024
December 18, 2023
Claims Court Says Military Did Not Infringe Software Rights